Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$29.84
-1.6%
$28.92
$26.12
▼
$37.09
$12.70B0.521.61 million shs1.16 million shs
Sanofi stock logo
SNY
Sanofi
$46.06
-2.2%
$43.00
$39.07
▼
$50.60
$114.24B0.314.28 million shs5.52 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
-1.63%-3.88%+1.83%+1.88%-7.56%
Sanofi stock logo
SNY
Sanofi
-2.25%-4.95%+11.26%+0.46%-7.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$29.84
-1.6%
$28.92
$26.12
▼
$37.09
$12.70B0.521.61 million shs1.16 million shs
Sanofi stock logo
SNY
Sanofi
$46.06
-2.2%
$43.00
$39.07
▼
$50.60
$114.24B0.314.28 million shs5.52 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
-1.63%-3.88%+1.83%+1.88%-7.56%
Sanofi stock logo
SNY
Sanofi
-2.25%-4.95%+11.26%+0.46%-7.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.91
Reduce$31.916.94% Upside
Sanofi stock logo
SNY
Sanofi
2.48
Hold$53.0015.07% Upside

Current Analyst Ratings Breakdown

Latest SNY and SNN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Sanofi stock logo
SNY
Sanofi
UpgradeHold (C-) ➝ Hold (C)
11/9/2026
Sanofi stock logo
SNY
Sanofi
UpgradeNeutral ➝ Outperform$57.00
11/5/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
DowngradeHold ➝ Strong Sell
11/2/2026
Sanofi stock logo
SNY
Sanofi
UpgradeSell (D+) ➝ Hold (C-)
10/9/2026
Sanofi stock logo
SNY
Sanofi
Initiated CoveragePeer Perform
10/8/2026
Sanofi stock logo
SNY
Sanofi
UpgradeSell (D) ➝ Sell (D+)
10/5/2026
Sanofi stock logo
SNY
Sanofi
Reiterated RatingBuy
10/1/2026
Sanofi stock logo
SNY
Sanofi
Reiterated RatingBuy
10/1/2026
Sanofi stock logo
SNY
Sanofi
Reiterated RatingNeutral
9/29/2026
Sanofi stock logo
SNY
Sanofi
Reiterated RatingBuy
9/24/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
DowngradeHold (C+) ➝ Hold (C)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$6.16B2.03$3.38 per share8.84$12.45 per share2.40
Sanofi stock logo
SNY
Sanofi
$49.35B2.26$6.91 per share6.67$34.77 per share1.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$625MN/AN/A13.262.06N/AN/AN/AN/A
Sanofi stock logo
SNY
Sanofi
$8.84B$2.0222.808.441.298.70%15.16%8.48%2/4/2027 (Estimated)

Latest SNY and SNN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2026Q3 2026
Sanofi stock logo
SNY
Sanofi
$1.56$2.04+$0.48$1.43$14.30 billion$17.25 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.591.98%N/AN/AN/A
Sanofi stock logo
SNY
Sanofi
$1.763.82%+6.46%87.13%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.62
2.14
1.11
Sanofi stock logo
SNY
Sanofi
0.20
1.12
0.27

Institutional Ownership

CompanyInstitutional Ownership
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
25.64%
Sanofi stock logo
SNY
Sanofi
14.03%

Insider Ownership

CompanyInsider Ownership
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.00%
Sanofi stock logo
SNY
Sanofi
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
16,988418.72 million414.53 millionOptionable
Sanofi stock logo
SNY
Sanofi
74,8462.42 billion2.40 billionOptionable

Recent News About These Companies

Insmed shares jump 18% as Sanofi weighs potential takeover
3 Big Pharma Dividend Stocks Built for Retirement Income
Insmed jumps on report of Sanofi takeover interest
Investors Purchase High Volume of Sanofi Put Options (NASDAQ:SNY)
US FDA approves Sanofi's genetic disorder drug
SNY:CA Balance Sheet
Sanofi Earnings Call Signals Growth Despite Pipeline Risks
Sanofi (NASDAQ:SNY) Stock Rated "Hold" by Sell-Side Brokerages

New MarketBeat Followers Over Time

Media Sentiment Over Time

Smith & Nephew SNATS stock logo

Smith & Nephew SNATS NYSE:SNN

$29.84 -0.48 (-1.58%)
Closing price 11/19/2026
Extended Trading
$29.83 -0.01 (-0.03%)
As of 11/19/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Sanofi stock logo

Sanofi NASDAQ:SNY

$46.06 -1.06 (-2.25%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$46.55 +0.49 (+1.06%)
As of 11/19/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.